Abstract
Programmed cell death ligand-1 (PD-L1) is a key target molecule of immunotherapy that is frequently overexpressed in bladder cancer. In the present study, we examined whether PD-L1 expression is associated with clinical outcomes in bladder cancer patients. We enrolled 102 bladder cancer patients treated with cystectomy at the Aomori Prefectural Hospital between April 2004 and May 2014. We conducted an immunohistochemical examination of PD-L1 expression using the SP142 assay. PD-L1 expression was scored at three diagnostic levels (0/1/2). Of the 102 patients, 82 were men (81.0%) and 20 were women (19.0%) (mean age 60 years, range 43-84 years). Sixty-six patients (64.8%) had previously undergone neoadjuvant chemotherapy [neoadjuvant (+) group]. During the mean observation period of 54.5 months, 42 patients had recurring disease (41.1%) and 34 died (33.3%). The 5-year cause-specific survival (CSS) rate was 66.6%; the 5-year disease-free survival (DFS) rate was 59.7%. In the neoadjuvant (+) group, the 5-year DFS rate was 65.0% for PD-L1 (-) patients and 31.7% for PD-L1 (+) patients (log-rank p = 0.006). In the neoadjuvant (+) groups, the 5-year CSS rate was 69.6% for PD-L1 (-) patients and 48.1% for PD-L1 (+) patients. Differences ...Continue Reading
References
Aug 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephen A BoorjianIgor Frank
Jun 24, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jun YangMohamed H Sayegh
Jun 24, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alison M PatersonArlene H Sharpe
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Oct 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel S ChenF Stephen Hodi
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Jul 19, 2014·Lancet·Caroline RobertAdil Daud
Nov 28, 2014·Nature·Thomas PowlesNicholas J Vogelzang
Nov 28, 2014·Nature·Roy S HerbstF Stephen Hodi
May 13, 2015·Oncology Reports·Yide HuangHang-Fai Kwok
Jan 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermottThomas Powles
Mar 14, 2016·Lancet·Louis FehrenbacherUNKNOWN POPLAR Study Group
May 14, 2016·Oncotarget·Rika FujiiJames W Hodge
May 29, 2016·Journal of Hematology & Oncology·Weijie MaTianhong Li
Jun 3, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel Morgensztern, Roy S Herbst
Jun 7, 2016·Clinical Lung Cancer·David PlanchardJean-Charles Soria
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe MassardNeil H Segal
Citations
Sep 4, 2018·Future Oncology·Ajaz Bulbul, Emilio Araujo-Mino
Oct 17, 2019·Frontiers in Pharmacology·Lei ZhuZhibin Li
Oct 20, 2020·Urologic Oncology·Yasukiyo MurakamiMasatsugu Iwamura
Dec 15, 2020·Urologic Oncology·Hirotaka HoriguchiChikara Ohyama